Jump to content

Alberto Mantovani

From Wikipedia, the free encyclopedia
Alberto Mantovani
Born (1948-10-29) October 29, 1948 (age 75)
Milan, Italy
Alma materUniversity of Milan
Known for
AwardsRobert Koch Prize, see text for others
Scientific career
FieldsImmunology
InstitutionsUniversity of Milan
Humanitas University
University of Brescia
Mario Negri Institute for Pharmacological Research
WebsitePage at Humanitas

Alberto Mantovani Commendatore OMRI (born 29 October 1948) is an Italian physician and immunologist. He is Scientific Director of Istituto Clinico Humanitas (Humanitas Clinical and Research Center), President and Founder of the Fondazione Humanitas per la Ricerca, and Professor of Pathology at the State University of Milan.[1] He is known for his works in the roles of the immune system in the development of cancer. His research on tumor-associated macrophages (TAM, an acronym he coined) established inflammation as one of the causes of cancer. He was the first to identify monocyte chemotactic protein - 1 / CCL2 in 1983, and PTX3 in 1997. His works revealed the existence of decoy receptors in cell-signalling. He has been the most cited scientist in Italy, and one of the ten most cited immunologists worldwide.[2]

Biography

[edit]

Mantovani was born in Milan[1] on 29 October 1948.[3] He studied medicine at the University of Milan and graduated (summa cum laude) in 1973. In 1976 he earned a specialization in oncology at the University of Pavia. Between 1973 and 1976, he worked as a visiting fellow at the Department of Tumor Immunology of the Chester Beatty Research Institute (now the Institute of Cancer Research) in Belmont, Sutton, England, where he continued the studies of Iwan Robert Evans and Peter Alexander. Between 1978 and 1979 he was a visiting fellow at the Laboratory of Immunodiagnosis at the National Institutes of Health in Bethesda, Maryland. In 1979 he was appointed Senior investigator in the Department of Tumor Immunology and Chemotherapy at the Istituto di Ricerche Farmacologiche "Mario Negri" in Milan. He became the Chief of Laboratory of the institute in 1981. In 1987 he worked at the Laboratory of Molecular Immunoregulation of NIH in Frederick, Maryland, as an Eleanor Roosvelt UICC Scholar. In 1994 he was promoted to Full Professor of General Pathology in the School of Medicine at the University of Brescia. He became Head of the Department of Immunology and Cell Biology at Istituto di Ricerche Farmacologiche "Mario Negri" in 1996. Between 2001 and 2014, he also served as Full Professor of General Pathology in the School of Medicine of the State University of Milan. Then he continued as Full Professor of General Pathology at Humanitas University in 2014. In 2005 he became the Scientific Director of Istituto Clinico Humanitas and President of Fondazione Humanitas per la Ricerca (under Humanitas University).[1][2]

Research activities

[edit]

Following the deepening of the studies by Robert Evans and Peter Alexander on the role of macrophages in tumour formation,[4] Mantovani discovered that macrophages, rather than helping to shrink the tumor, help it to grow and progress.[5] He gave the acronym for such tumor-associated macrophages as TAM. His work in 2013 showed that targeting TAM is useful for cancer treatment.[6] In 1983, his research team has discovered a protein, known as monocyte chemotactic protein - 1 / CCL2, which is part of the large superfamily of chemokines, which belong to the family of cytokines. His works help to establish the concept of "decoy receptors". From the study of the regulation of the cytokines, Mantovani was able to identify the operating principle of the decoy receptor for interleukin - 1. In 1993, his team showed interleukin-1 type II receptor acts as a decoy in the activity of interleukin 1.[7] His team identified the first member of the long pentraxins, named PTX3 in 1997. The discovery was published in a series of papers.[8][9][10] His team demonstrated in 2005 that the chemokine receptor D6 acts as a decoy and scavenger receptor for inflammatory chemokines.[11] In 2015 his research, published in the journal Cell,[12] showed that PTX3 gene is capable of curbing cancer by controlling inflammation.

Works

[edit]
  • Tumor-Associated Leukocytes. 1994.
  • Chemokines. 1999.
  • Pharmacology of cytokines. 2000.
  • Gianfranco Bazzoni; Elisabetta Dejana; Alberto Mantovani (2006). Piccin (ed.). L' endotelio. Fisiopatologia, basi molecolari, implicazioni terapeutiche. Padova. ISBN 978-88-299-1845-4.{{cite book}}: CS1 maint: location missing publisher (link)
  • Targeted therapies in cancer: myth or reality?. Springer. 2008.
  • Academic press, ed. (2013). Cancer Immunotherapy.
  • Macrophages: biology and role in the pathology of diseases. Springer. 2014.
  • I guardiani della vita. Milan: Baldini e Castoldi. 2014.
  • Immunità e vaccini. Perché è giusto proteggere la nostra salute e quella dei nostri figli. Segrate: Mondadori. 2016.

Scientific Publications

[edit]

Awards

[edit]
  • 1998 - Biotech Award, Amgen - Dompe' - Vector Securities International,[13]
  • 2000 - Marie T. Bonazinga Award, Boston, USA[14]
  • 2004 - Guido Venosta Award, Italian Foundation for Cancer Research
  • 2006 - European Immunology Award, European Immunology Societies
  • 2007 - Galileo Galilei Prize for Research in Biomedical Sciences[15]
  • 2007 - PISO Award[14]
  • 2009 - William Harvey Medal, William Harvey Research Institute
  • 2011 - IMID Award for Excellence in Immunology
  • 2013 - Rusconi Lecture, Anna Villa e Felice Rusconi Foundation and University of Insubria
  • 2014 - Rosa Camuna Prize, Lombardy Region
  • 2014 - Barbara Baldacci Award, University of Bari
  • 2015 - Milstein Award, International Cytokine and Interferon Society (ICIS)
  • 2015 - Ferrari Soave Award, Academy of Sciences of Turin
  • 2015 - The Albert Struyvenberg Medal, European Society of Clinical Investigation
  • 2016 - OECI Oncology Prize, Organization of European Cancer Institutes
  • 2016 - Robert Koch Prize, Robert Koch Foundation
  • 2016 - Merck Serono Literary Prize
  • 2016 - Feltrinelli Prize, Lincean Academy
  • 2019 - Pezcoller Foundation-AACR International Award for Cancer Research[16]

Honors

[edit]

Mantovani was appointed "Commander" of the Order of Merit of the Italian Republic in 2005.[17] He was Fellow of the Italian Association Against Leukemias in 1973, and Fellow of the Anna Villa Rusconi Foundation in 1974.[2] He was vice-president/president the International Union of Immunological Societies from 2013 to 2016. He served on the board of the Global Alliance for Vaccines and Immunization (GAVI) between 2007 and 2010. He was president of the International Cytokine Society during 2009–2010.[18]

References

[edit]
  1. ^ a b c "Biography—Alberto Mantovani, MD". Cancer and Metastasis Reviews. 29 (2): 239. 2010. doi:10.1007/s10555-010-9219-2.
  2. ^ a b c "Mantovani Alberto, MD". www.humanitas-research.org. Humanitas Clinical and Research Center, Italy. Archived from the original on 25 June 2016. Retrieved 27 July 2016.
  3. ^ "Curriculum vitae: Mantovani Alberto". www.forumecm.it. Retrieved 29 July 2016.
  4. ^ Evans, R.; Alexander, P. (1972). "Mechanism of Immunologically Specific Killing of Tumour Cells by Macrophages". Nature. 236 (5343): 168–170. Bibcode:1972Natur.236..168E. doi:10.1038/236168a0. PMID 4553694. S2CID 4256131.
  5. ^ Bonavita, E; Galdiero, MR; Jaillon, S; Mantovani, A (2015). Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. Vol. 128. pp. 141–71. doi:10.1016/bs.acr.2015.04.013. ISBN 9780128023167. PMID 26216632. {{cite book}}: |journal= ignored (help)
  6. ^ "The Milstein Award: Alberto Montavani". International Cytokine and Interferon Society (ICIS). Archived from the original on 7 August 2016. Retrieved 29 July 2016.
  7. ^ Colotta, F; Re, F; Muzio, M; Bertini, R; Polentarutti, N; Sironi, M; Giri, J.; Dower, S.; Sims, J.; Mantovani, A (1993). "Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4". Science. 261 (5120): 472–475. Bibcode:1993Sci...261..472C. doi:10.1126/science.8332913. PMID 8332913.
  8. ^ Vouret-Craviari, V; Matteucci, C; Peri, G; Poli, G; Introna, M; Mantovani, A (1997). "Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan". Infection and Immunity. 65 (4): 1345–1350. doi:10.1128/IAI.65.4.1345-1350.1997. PMC 175138. PMID 9119472.
  9. ^ Basile, A; Sica, A; d'Aniello, E; Breviario, F; Garrido, G; Castellano, M; Mantovani, A; Introna, M (1997). "Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation". The Journal of Biological Chemistry. 272 (13): 8172–8178. doi:10.1074/jbc.272.13.8172. PMID 9079634.
  10. ^ Bottazzi, B; Vouret-Craviari, V; Bastone, A; De Gioia, L; Matteucci, C; Peri, G; Spreafico, F; Pausa, M; D'Ettorre, C; Gianazza, E; Tagliabue, A; Salmona, M; Tedesco, F; Introna, M; Mantovani, A (1997). "Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component". The Journal of Biological Chemistry. 272 (52): 32817–32823. doi:10.1074/jbc.272.52.32817. PMID 9407058.
  11. ^ de la Torre, Yeny Martinez; Locati, Massimo; Buracchi, Chiara; Dupor, Jana; Cook, Donald N.; Bonecchi, Raffaella; Nebuloni, Manuela; Rukavina, Daniel; Vago, Luca; Vecchi, Annunciata; Lira, Sergio A.; Mantovani, Alberto (2005). "Increased inflammation in mice deficient for the chemokine decoy receptor D6". European Journal of Immunology. 35 (5): 1342–1346. doi:10.1002/eji.200526114. PMID 15789340. S2CID 39418935.
  12. ^ Bonavita, Eduardo; Gentile, Stefania; Rubino, Marcello; Maina, Virginia; Papait, Roberto; Kunderfranco, Paolo; Greco, Carolina; Feruglio, Francesca; Molgora, Martina; Laface, Ilaria; Tartari, Silvia; Doni, Andrea; Pasqualini, Fabio; Barbati, Elisa; Basso, Gianluca; Galdiero, Maria Rosaria; Nebuloni, Manuela; Roncalli, Massimo; Colombo, Piergiuseppe; Laghi, Luigi; Lambris, John D.; Jaillon, Sébastien; Garlanda, Cecilia; Mantovani, Alberto (2015). "PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer". Cell. 160 (4): 700–714. doi:10.1016/j.cell.2015.01.004. PMID 25679762.
  13. ^ "Biotecnologie: Ricerca e Futuro a Biotec Award 1998". 22 June 1998.
  14. ^ a b "Biography—Alberto Mantovani, MD". Cancer and Metastasis Reviews. 29 (2): 239. 2010. doi:10.1007/s10555-010-9219-2.
  15. ^ "Featuring the Guest Editor Alberto Mantovani". 4 December 2020.
  16. ^ "THE PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD". Pezcoller Foundation. Retrieved 6 November 2019.
  17. ^ "Commendatore Ordine al Merito della Repubblica Italiana". presidenti.quirinale.it (in Italian). Presidenza della Republica. Archived from the original on 18 August 2016. Retrieved 28 July 2016.
  18. ^ "Prof Alberto Mantovani". Efranat, Inc. Archived from the original on 19 August 2016. Retrieved 28 July 2016.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Alberto_Mantovani&oldid=1231250555"